A Mac-2 Binding Protein Glycosylation Isomer-Based Risk Model Predicts Hepatocellular Carcinoma in HBV-Related Cirrhotic Patients on Antiviral Therapy

Chien Hung Chen*, Tsung Hui Hu, Jing Houng Wang, Hsueh Chou Lai, Chao Hung Hung, Sheng Nan Lu, Cheng Yuan Peng*

*Corresponding author for this work

Research output: Contribution to journalJournal Article peer-review

Abstract

Mac-2 binding protein glycosylation isomer (M2BPGi) has not been used in a risk score to predict hepatocellular carcinoma (HCC). We enrolled 1003 patients with chronic hepatitis B and cirrhosis receiving entecavir or tenofovir therapy for more than12 months to construct an HCC risk score. In the development cohort, Cox regression analysis identified male gender, age, platelet count, AFP and M2BPGi levels at 12 months of treatment as independent risk factors of HCC. We developed the HCC risk prediction model, the ASPAM-B score, based on age, sex, platelet count, AFP and M2BPGi levels at 12 months of treatment, with the total scores ranging from 0 to 11.5. This risk model accurately classified patients into low (0–3.5), medium (4–7), and high (>7) risk in the development and validation groups (p < 0.001). The areas under the receiver operating characteristic curve (AUROC) of 3-, 5- and 9-year risks of HCC were 0.742, 0.728 and 0.719, respectively, in the development cohort. All AUROC between the ASPAM-B and APA-B, PAGE-B, RWS-HCC and THRI scores at 3–9 years were significantly different. The M2BPGi-based risk model exhibited good discriminant function in predicting HCC in cirrhotic patients who received long-term antiviral treatment.

Original languageEnglish
Article number5063
JournalCancers
Volume14
Issue number20
DOIs
StatePublished - 10 2022

Bibliographical note

Publisher Copyright:
© 2022 by the authors.

Keywords

  • AFP
  • M2BPGi
  • cirrhosis
  • hepatocellular carcinoma
  • risk model

Fingerprint

Dive into the research topics of 'A Mac-2 Binding Protein Glycosylation Isomer-Based Risk Model Predicts Hepatocellular Carcinoma in HBV-Related Cirrhotic Patients on Antiviral Therapy'. Together they form a unique fingerprint.

Cite this